Lung Trials

SCLC

Trial No.: AstraZeneca  D419QC00001 Caspian

Trial Name:

A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination with Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease

On Hold Pending Availablilty of Etopside

NSCLC

Trial No.: BMS CA209-384

Trial Name:

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240mg Every 2 Weeks vs Nivolumab 480mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3mg/kg or 240 mg Every 2 Weeks

Fort Wayne North Office
(260) 484-8830
11143 Parkview Plaza Drive, Suite 100
Fort Wayne, Indiana 46845

Fort Wayne South Office
(260) 436-0800
7910 West Jefferson Boulevard, Suite 108
Fort Wayne, Indiana 46804

©2018 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.